• Oncology
  • Exited

Syndax Pharmaceuticals, Inc. is developing entinostat for the treatment of patients with therapy-resistant cancers. Entinostat is designed to prolong the effectiveness of current cancer treatments through an epigenetic mechanism and has been designated a Breakthrough Therapy by the FDA based on its success in a randomized Phase 2b trial. Entinostat is an oral, class 1 selective HDAC inhibitor that is being evaluated in combination with exemestane in a pivotal Phase 3 clinical study for the treatment of estrogen receptor positive metastatic breast cancer. Syndax holds rights to entinostat in all major markets.